The Infectious Diseases Society of America (IDSA) Standards and Practice Guidelines Committee collaborated with partner organizations to convene a panel of 10 experts on healthcare-associated ventriculitis and meningitis. The panel represented pediatric and adult specialists in the field of infectious diseases and represented other organizations whose members care for patients with healthcare-associated ventriculitis and meningitis (American Academy of Neurology, American Association of Neurological Surgeons, and Neurocritical Care Society). The panel reviewed articles based on literature reviews, review articles and book chapters, evaluated the evidence and drafted recommendations. Questions were reviewed and approved by panel members. Subcategories were included for some questions based on specific populations of patients who may develop healthcare-associated ventriculitis and meningitis after the following procedures or situations: cerebrospinal fluid shunts, cerebrospinal fluid drains, implantation of intrathecal infusion pumps, implantation of deep brain stimulation hardware, and general neurosurgery and head trauma. Recommendations were followed by the strength of the recommendation and the quality of the evidence supporting the recommendation. Many recommendations, however, were based on expert opinion because rigorous clinical data are not available. These guidelines represent a practical and useful approach to assist practicing clinicians in the management of these challenging infections.
Meningitis may not only be acquired in the community setting, but may be associated with a variety of invasive procedures or head trauma. The latter group has often been classified as nosocomial meningitis because a different spectrum of microorganisms (ie, resistant gram-negative bacilli and staphylococci) is the more likely the etiologic agents, and different pathogenic mechanisms are associated with the development of this disease. Although many of these patients present with clinical symptoms during hospitalization, ventriculitis and meningitis may develop after hospital discharge or even many years later. We, therefore, prefer the term "healthcare-associated ventriculitis and meningitis" to be more representative of the diverse mechanisms (that include placement of devices) that can lead to these serious illnesses.
Summarized below are recommendations for the evaluation, diagnosis, and management of healthcare-associated ventriculitis and meningitis, specifically addressing the approach to infections associated with cerebrospinal fluid shunts, cerebrospinal fluid drains, intrathecal drug (eg, baclofen) therapy, deep brain stimulation hardware, and neurosurgery and head trauma. These infections may be difficult to diagnose because changes in cerebrospinal fluid parameters are often subtle, making it hard to determine if the abnormalities are related to infection, related to placement of devices, or following neurosurgery. Many of our recommendations are based on expert opinion because rigorous clinical data are not available and the likelihood that clinical trials will be conducted to answer some of these questions is low. Our goal was to develop guidelines that offered a practical and useful approach to assist practicing clinicians in the management of these challenging infections. The panel followed a process used in the development of other IDSA guidelines that included a systematic weighting of the strength of recommendations and quality of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system ( Figure 1 ) [1] [2] [3] [4] [5] . A detailed description of the methods, background, and evidence summaries that support each recommendation can be found in the full text of the guidelines. 
I. What Are the Typical Symptoms and Signs in Patients With

III. What Specific Tests of Cerebrospinal Fluid can be used to Confirm the Patient has Healthcare-Associated Ventriculitis and Meningitis?
Recommendations 30. An elevated CSF lactate or an elevated CSF procalcitonin, or the combination of both, may be useful in the diagnosis of healthcare-associated bacterial ventriculitis and meningitis (weak, moderate). 31. An elevated serum procalcitonin may be useful in differentiating between CSF abnormalities due to surgery or intracranial hemorrhage from those due to bacterial infection (weak, low). 32. Nucleic acid amplification tests, such as polymerase chain reaction, on CSF may both increase the ability to identify a pathogen and decrease the time to making a specific diagnosis (weak, low). 33. Detection of β-D-glucan and galactomannan in CSF may be useful in the diagnosis of fungal ventriculitis and meningitis (strong, moderate). ) ; for strains that demonstrate carbapenem resistance, colistimethate sodium or polymyxin B (either agent administered by the intravenous and intraventricular routes) is recommended (strong, moderate). 52. Prolonged infusion of meropenem (each dose administered over 3 hours) may be successful in treating resistant gram-negative organisms (weak, low). 53. For treatment of infection caused by Candida species, based on in vitro susceptibility testing, liposomal amphotericin B, often combined with 5-flucytosine, is recommended (strong, moderate); once the patient shows clinical improvement, therapy can be changed to fluconazole if the isolated species is susceptible (weak, low).
IV. What is the Role of Imaging in Patients with
For treatment of infection caused by Aspergillus or
Exserohilum species, voriconazole is recommended (strong, low).
VII. What is the Role of Intraventricular Antimicrobial Therapy in Patients with Healthcare-Associated Ventriculitis and Meningitis?
Recommendations 55. Intraventricular antimicrobial therapy should be considered for patients with healthcare-associated ventriculitis and meningitis in which the infection responds poorly to systemic antimicrobial therapy alone (strong, low). 56. When antimicrobial therapy is administered via a ventricular drain, the drain should be clamped for 15-60 minutes to allow the agent to equilibrate throughout the CSF (strong, low). 57. Dosages and intervals of intraventricular antimicrobial therapy should be adjusted based on CSF antimicrobial concentrations to 10-20 times the MIC of the causative microorganism (strong, low), ventricular size (strong, low), and daily output from the ventricular drain (strong, low). 
VIII. What is the Optimal Duration of Antimicrobial Therapy in
